Amicus Therapeutics Presents Promising Developments for Pompe Disease at World Muscle Society Congress

Amicus Therapeutics, a global biotechnology company dedicated to developing innovative medicines for rare diseases, has announced its participation in the 28th Annual Congress of the World Muscle Society (WMS) held in Charleston, SC from October 3-7, 2023. The company will present significant advancements in its development program for Pompe disease through an oral presentation and four poster sessions.

The oral presentation titled “104-week efficacy and safety of cipaglucosidase alfa + miglustat in patients with late-onset Pompe disease previously treated with alglucosidase alfa” will showcase the positive results of a two-year study on the combination therapy. This research demonstrates the potential of cipaglucosidase alfa and miglustat in improving the outcomes for patients with late-onset Pompe disease.

Additionally, Amicus Therapeutics will present four posters highlighting various aspects of their Pompe disease development program. One poster will focus on the positive impact of switching treatment to cipaglucosidase alfa plus miglustat on motor function and quality of life in patients with late-onset Pompe disease. Another poster will present an effect size analysis comparing cipaglucosidase alfa plus miglustat to alglucosidase alfa in adults with late-onset Pompe disease who have previously undergone enzyme replacement therapy (ERT). The safety of home administration of cipaglucosidase alfa plus miglustat will also be discussed in one of the posters. Lastly, a real-world evidence study conducted in Sweden will shed light on the disease burden, treatment patterns, and healthcare resource utilization associated with Pompe disease.

Amicus Therapeutics remains committed to its patient-centric approach and aims to develop groundbreaking therapies for rare diseases. The company’s participation in the WMS Congress demonstrates its dedication to advancing the field of Pompe disease research and improving the lives of patients worldwide.

For more information on the World Muscle Society 2023 Congress, please visit wms2023.com. To learn more about Amicus Therapeutics and its mission, visit their website at www.amicusrx.com. Stay updated on their latest developments by following them on Twitter and LinkedIn.

Contact:
Investors:
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079